TAXUS Express2 Over-the-wire Paclitaxel-Eluting Coronary Stent System
Description:The
TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3.75 mm in diameter....
Company:Boston Scientific Corporation
TAXUS Express2 Monorail Paclitaxel-Eluting Coronary Stent System
Description:The
TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3.75 mm in diameter....
Company:Boston Scientific Corporation
New Study Suggests Better Patient Outcomes with CYPHER
Sirolimus-Eluting Coronary Stent than with Taxus Stent in
Real-World Clinical Settings
Registry Analysis Published in Journal Heart Finds
Taxus Stent,Implantation of Multiple Stents and Small Vessel Size To BeIndependent Predictors of Need for Another Procedure MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX NewsNetwork/ -- An analysis of data from the Western Denmark HeartRegistry found that patients who received the CYPHER(R)Sirolimus-eluting Coronary...
Positive Results for Second-Generation Taxus Liberte Coronary Stent
System Highlighted in Journal of American College of Cardiology
NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- BostonScientific Corporation today welcomed the publication of an articlein the Journal of of Cardiology (JACC) reviewing the
TAXUS ATLASclinical trial, which evaluates the Company's second-generation
TAXUS(R) Liberte(TM)(1) paclitaxel-eluting stent system. Thearticle in the April 24 edition of JACC concluded that the shorterprocedure...
SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus
Drug-Eluting Coronary Stent Systems
SPIRIT FIRST follow-up analysis shows no stent thrombosis or MACEafter one year NATICK, Mass. and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todaywelcomed the results of additional data from the SPIRIT FIRST, IIand III Clinical Trials, reaffirming prior safety and efficacy datafor the market-leading
TAXUS(R) Express2(TM) Paclitaxel-ElutingCorona...
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes
for Moderate-Release Paclitaxel-Eluting Stent at Four Years
Trial results report no new stent thrombosis after two years inhigh-risk patient population NATICK, Mass., and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced four-year follow-up data from its
TAXUS VI clinicaltrial. The data demonstrated that the safety and efficacy benefitsassociated with a moderate-release formulation of the
TAXUS(R)...
Abbott's Xience V Everolimus Eluting Coronary Stent Superior to
Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
- XIENCE V Demonstrates Superiority in Primary Endpoint ofIn-Segment Late Loss, Non-Inferiority in Major Secondary Endpointof Target Vessel Failure and Superiority in Major Adverse CardiacEvents (MACE) in the SPIRIT III U.S. Trial - ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ -- Datapresented today from Abbott's SPIRIT III U.S. pivotal clinicaltrial at the of Cardiology's 56t...